Exploring the views of infection consultants in England on a novel delinked funding model for antimicrobials: the SMASH study.

ABSTRACT:

Objectives

A novel 'subscription-type' funding model was launched in England in July 2022 for ceftazidime/avibactam and cefiderocol. We explored the views of infection consultants on important aspects of the delinked antimicrobial funding model.

Methods

An online survey was sent to all infection consultants in NHS acute hospitals in England.

Results

The response rate was 31.2% (235/753). Most consultants agreed the model is a welcome development (69.8%, 164/235), will improve treatment of drug-resistant infections (68.5%, 161/235) and will stimulate research and development of new antimicrobials (57.9%, 136/235). Consultants disagreed that the model would lead to reduced carbapenem use and reported increased use of cefiderocol post-implementation. The presence of an a

SUBMITTER: Baltas I 

PROVIDER: S-EPMC10391702 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature